TMCnet News

Research and Markets: United States Pompe Disease Market 2015-2019 - Special Provision for Orphan Drugs a Major Market Driver
[November 24, 2015]

Research and Markets: United States Pompe Disease Market 2015-2019 - Special Provision for Orphan Drugs a Major Market Driver


Research and Markets (http://www.researchandmarkets.com/research/22t2d6/pompe_disease) has announced the addition of the "Pompe Disease Market in the US 2015-2019" report to their offering.

The pompe disease market in the US to grow at a CAGR of 10.68% over the period 2014-2019

This report covers the present scenario and the growth prospects of the pompe disease market in US for the period 2015-2019. To calculate the market size, the report considers revenue from the sales of the drugs available in the US market and the drug candidates that are in various phases of development for the treatment of Pompe disease.

The report also presents the vendor landscape and a corresponding detailed analysis of the major vendors in the market. In addition, it discusses the major drivers that influene the growth and the challenges faced by the vendors and the market at large, as well as the key trends that contribute to the growth the market. The report includes a discussion of the key vendors operating in this market.



Highlights

The market is expected to witness certain emerging trends. The rise in awareness programs to treat Pompe disease patients is one such trend. It increases the treatment seeking rate among patients, which results in an increase in overall consumption of medicines.


According to the report, the special provision for orphan drugs given by the FDA in terms of market exclusivity and tax benefits for a specified time, is one factor. Also, the presence of high unmet needs for appropriate drugs is another major factor propelling the growth of the market.

Further, the report states that the limited patient population is a major factor hindering the growth of the market. It is known to hamper the clinical studies of a drug candidate under development for the treatment of Pompe disease.

Key vendors

  • Amicus Therapeutics
  • BioMarin Pharmaceutical
  • Genzyme

Other prominent vendors

  • Audentes Therapeutics
  • EpiVax
  • Oxyrane
  • Sangamo BioSciences
  • Valerion Therapeutics

For more information visit http://www.researchandmarkets.com/research/22t2d6/pompe_disease


[ Back To TMCnet.com's Homepage ]